40397-96-4 Usage
Uses
Used in Pharmaceutical Industry:
4-CHLORO-3-NITROPHENYL ISOCYANATE is used as a key intermediate in the synthesis of various pharmaceutical compounds for its ability to readily react with other molecules, facilitating the creation of new drug entities.
Used in Agricultural Chemical Industry:
In the agricultural sector, 4-CHLORO-3-NITROPHENYL ISOCYANATE is utilized as a precursor in the production of agrochemicals, contributing to the development of pesticides and other crop protection agents.
Used in Chemical Research:
4-CHLORO-3-NITROPHENYL ISOCYANATE serves as a valuable research tool in chemical laboratories, where its reactivity is exploited to study reaction mechanisms and to develop new synthetic methodologies.
Used in Material Science:
4-CHLORO-3-NITROPHENYL ISOCYANATE is employed in the development of novel materials, such as polymers and coatings, that can benefit from the unique properties imparted by the isocyanate functional group and the attached chloro and nitro substituents.
Note: The specific uses listed above are hypothetical and provided as examples, as the original materials did not include explicit applications for 4-CHLORO-3-NITROPHENYL ISOCYANATE. The actual uses would depend on the compound's chemical properties and the needs of the industries involved.
Check Digit Verification of cas no
The CAS Registry Mumber 40397-96-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,0,3,9 and 7 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 40397-96:
(7*4)+(6*0)+(5*3)+(4*9)+(3*7)+(2*9)+(1*6)=124
124 % 10 = 4
So 40397-96-4 is a valid CAS Registry Number.
InChI:InChI=1/C7H3ClN2O3/c8-6-2-1-5(9-4-11)3-7(6)10(12)13/h1-3H
40397-96-4Relevant academic research and scientific papers
Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer
Akwii, Racheal,Alvina, Karina,Ashraf-Uz-Zaman, Md,Farshbaf, Mohammad Jodeiri,German, Nadezhda A.,Kallem, Raja Reddy,Mikelis, Constantinos M.,Putnam, William,Sajib, Md Sanaullah,Shahi, Sadisna,Trippier, Paul C.,Wang, Wei,Zhang, Ruiwen
, (2020/10/12)
Triple-negative breast cancer (TNBC) is an aggressive type of cancer characterized by higher metastatic and reoccurrence rates, where approximately one-third of TNBC patients suffer from the metastasis in the brain. At the same time, TNBC shows good responses to chemotherapy, a feature that fuels the search for novel compounds with therapeutic potential in this area. Recently, we have identified novel urea-based compounds with cytotoxicity against selected cell lines and with the ability to cross the blood-brain barrier in vivo. We have synthesized and analyzed a library of more than 40 compounds to elucidate the key features responsible for the observed activity. We have also identified FGFR1 as a molecular target that is affected by the presence of these compounds, confirming our data using in silico model. Overall, we envision that these compounds can be further developed for the potential treatment of metastatic breast cancer.
